BMY•benzinga•
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Summary
Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on October 31, 2024 by benzinga